Quanterix: Trading Below 1x Sales Despite A Changing Story

Quanterix is transitioning from persistent losses to a turnaround, driven by a new, highly experienced management team post-Akoya acquisition. QTRX targets cash flow breakeven in H2 2026, leveraging cost synergies, commercial execution, and a large installed base for recurring revenue. The Alzheimer's blood test and broader biomarker platform offer significant growth potential, though execution and adoption risks remain. I assign a Buy rating, seeing 140-150% upside over three years if management delivers on guidance and the market re-rates QTRX.

Quanterix (NASDAQ: QTRX ) has a history of persistent losses, but following the Akoya acquisition, a new management team with an incredible track record for a microcap has shifted the focus toward commercial execution, cost synergies.